Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in ScandinaviaGlobeNewsWire • 07/20/23
Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed JournalGlobeNewsWire • 07/17/23
Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac RegenerationGlobeNewsWire • 07/05/23
Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular SyndromeAccesswire • 06/15/23
Altamira Therapeutics Announces Publication of Peer-Reviewed Article on Peptide-Based RNA Delivery for Extrahepatic TargetsAccesswire • 05/31/23
Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic RhinitisAccesswire • 05/24/23
Altamira Therapeutics Provides Business Update, Reports FY 2022 Financial ResultsAccesswire • 05/16/23
Altamira Therapeutics to Host Fiscal Year 2022 Financial Results and Business Update Call on May 16th 2023Accesswire • 05/12/23
Altamira Therapeutics CEO & Chairman to Present at Sidoti Micro-Cap Virtual Conference May 10-11Accesswire • 05/01/23
Altamira Therapeutics Announces Publication of Positive Results from Phase 2 Trial with AM-125 in Acute Vestibular Syndrome in Leading Peer Reviewed JournalAccesswire • 04/12/23
Altamira Therapeutics Positions its Patented SemaPhore mRNA Delivery Platform as Versatile and Efficient Alternative to Lipid NanoparticlesAccesswire • 04/11/23
Altamira Therapeutics Reports Positive Conclusions from Independent Meta-Analysis of Clinical Studies with Betahistine in Treatment of Most Common Cause of VertigoAccesswire • 04/10/23
Altamira Therapeutics' SemaPhore Delivery Platform Shows Significant Synergis-tic Effects of ZBTB46 mRNA with PD1 Immunotherapy in Control of Tumor Growth in Animal ModelGlobeNewsWire • 03/22/23
Altamira Therapeutics' SemaPhore RNA Delivery Platform Drives Effective Treatment of Osteoarthritis with mRNA in Animal ModelAccesswire • 03/15/23
Clinical Study Demonstrates Bentrio's Superior Nasal Residence Time and Rheological PropertiesAccesswire • 03/03/23
Altamira Therapeutics Files Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer TreatmentGlobeNewsWire • 02/27/23